Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin versus metformin for insulin resistance and follicular fluid biomarkers in women with polycystic ovary syndrome
IRCT20240122060763N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in polycystic ovary syndrome (PCOS) comparing Atorvastatin with Metformin (2 arms). Primary endpoints: Plasma insulin resistance, Follicular fluid antioxidants and 2 more. Started Feb 2024; status: completed.
02
Drugs
atorvastatinmetformin
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on IRCT20240122060763N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240122060763N1.